Covid-19: Aspen Pharmacare eyes Serum Institute model as it seeks licence to make JnJ vaccine
Johannesburg: South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.
"At the moment, J&J could take all the product we make because it's their product, and sell it to Europe, for example, sell it to the U.S. or Korea, wherever they choose to. We have no say in that," he told Reuters.
Read also: Reliance Life Sciences gets DCGI approval for COVID vaccine trial
"It's like Serum where they get the licences to manufacture. It's not a foreign model and it's very exciting," he said on the licensing talks.
Read also: Second dose provides strong boost against Covid-19: JnJ
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.